RxDoctor Payments DataLook up a doctor →

Joseph Beck

Hematology & Oncology · Fayetteville, ARNPI 1952372120

Payments from drug & device makers

$33,801,182in general payments, 2019–2025

Across 2,610 payments — averaging $12,951 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$11.1M
  • AstraZeneca$6.6M
  • Pfizer$5.7M
  • Array Biopharma Inc$2.2M
  • Merck$1.7M
  • Eli Lilly$1.6M
  • plus $5M from 54 others
$91,941in research payments, 2019–2025

Across 41 payments — averaging $2242.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$59K
  • Eli Lilly$31K
  • Novartis$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis187$11,088,315
AstraZeneca80$6,558,919
Pfizer580$5,704,634
Array Biopharma Inc177$2,166,467
Merck75$1,717,543
Eli Lilly127$1,614,367
AbbVie293$965,960
E.r. Squibb & Sons, L.L.C.51$876,705
Seagen Inc.218$794,029
Genentech, Inc.184$734,918
Astrazeneca UK Limited6$592,586
Daiichi Sankyo Inc.82$249,377
GSK75$243,753
Stemline Therapeutics Inc.67$154,098
F. Hoffmann-la Roche AG22$64,596
Bristol Myers Squibb12$61,142
Roche Products Limited23$48,167
Gilead(2 entities)55$45,858
Exelixis Inc.9$24,238
Tesaro, Inc.11$18,701
Immunomedics, Inc.2$12,749
Novocure GmbH6$12,481
Halozyme Inc3$11,415
Mirati Therapeutics, Inc.5$10,618
EMD Serono, Inc.10$10,094
Novocure Inc.2$9,011
Janssen Research & Development, LLC13$6,284
Johnson & Johnson(2 entities)43$872
Puma Biotechnology, Inc.21$301
Sumitomo Pharma America, Inc.17$298
Ares Trading SA1$227
Genentech USA, Inc.12$200
Biontech SE2$184
Sanofi12$179
Amgen10$144
Regeneron Healthcare Solutions, Inc.8$119
Pharmacyclics LLC, An Abbvie Company4$115
Lilly USA, LLC8$102
Boehringer Ingelheim6$97
Ipsen Biopharmaceuticals, Inc6$87
ADC Therapeutics America, Inc.5$83
Foundation Medicine, Inc.2$81
Jazz Pharmaceuticals Inc.6$77
Eisai Inc.6$75
Astellas Pharma US Inc5$63
Dendreon Pharmaceuticals LLC4$59
Iovance Biotherapeutics, Inc.4$55
Sobi, Inc3$51
Recordati_rare_diseases_inc.3$50
Rigel Pharmaceuticals, Inc.4$50
Beigene USA, Inc.3$43
Incyte Corporation3$42
Clovis Oncology, Inc.4$36
Heron Therapeutics, Inc.4$35
Takeda Pharmaceuticals U.S.A., Inc.2$35
Verity Pharmaceuticals Inc.2$29
Tersera Therapeutics LLC2$27
Blue Earth Diagnostics2$26
Morphosys, US Inc.2$26
Bayer2$24

How this compares

$33,801,182 in reported general payments places this provider in the 95th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$5,115,707
Medicare patients
1,460
Services billed
234,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fayetteville

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →